This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
by Kinjel Shah
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
What's in the Cards for Medtronic (MDT) in Q1 Earnings?
by Zacks Equity Research
Going by the industry-wide macro trend, we expect Medtronic (MDT) to once again report an adverse effect related to the global supply chain issues in fiscal Q1.
Zacks Market Edge Highlights: Merck, PepsiCo, Honeywell, Microsoft and PNC Financial
by Zacks Equity Research
Merck, PepsiCo, Honeywell, Microsoft and PNC Financial have been highlighted in this Market Edge article.
The Story of the Greatest Mom and Pop Investor Ever
by Tracey Ryniec
Anne Scheiber grew $5,000 into $22 million over 50 years. How'd she do it?
Merck (MRK) Enters Into Circular RNA Collaboration With Orna
by Zacks Equity Research
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids
by Zacks Equity Research
With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.
Here's Why You Should Retain Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
Is Invesco Dow Jones Industrial Average Dividend ETF (DJD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DJD
Illumina (ILMN) Q2 Earnings Miss Estimates, Slashes '22 View
by Zacks Equity Research
Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth
by Zacks Equity Research
bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy.
National Vision (EYE) Q2 Earnings Top Mark, Revenue View Cut
by Zacks Equity Research
National Vision (EYE) is simultaneously facing demand headwinds across its network of stores, given the current macro environment, as well as supply challenges.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.
J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023
by Zacks Equity Research
J&J (JNJ) will stop selling its talcum-based baby powder globally from next year. Though reports claim that the use of the talc causes cancer, JNJ maintains its stance that this product is safe.
STERIS (STE) Gains From Cantel Buyout, Supply Chain Issue Stays
by Zacks Equity Research
Revenue growth at STERIS' (STE) Applied Sterilization Technologies is driven by increased demand from medical device and biopharma customers.
Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.
Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.
Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.
SmileDirectClub (SDC) Q2 Earnings Lag Estimates, Guidance Cut
by Zacks Equity Research
SmileDirectClub (SDC) witnesses a drop in both net and financing revenues on a year-over-year basis.
Q2 Earnings Scorecard and Analyst Reports for Roche, Adobe & McDonald's
by Sheraz Mian
Today's Research Daily features update on the Q2 earnings season and new research reports on Roche (RHHBY), Adobe (ADBE), and McDonald's (MCD).
Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up
by Zacks Equity Research
Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.